Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
KRYS

KRYS - Krystal Biotech Inc Stock Price, Fair Value and News

$272.66-4.70 (-1.69%)
Market Closed

73/100

KRYS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

73/100

KRYS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$361.77

Target 3M

$299.83

Target 6M

$318.97

KRYS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

KRYS Price Action

Last 7 days

-4.7%

Last 30 days

7.5%

Last 90 days

44.2%

Trailing 12 Months

71.3%

KRYS RSI Chart

KRYS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

KRYS Valuation

Market Cap

7.9B

Price/Earnings (Trailing)

39.75

Price/Sales (Trailing)

21.19

EV/EBITDA

39.04

Price/Free Cashflow

47.75

KRYS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$361.77

Target 3M

$299.83

Target 6M

$318.97

KRYS Fundamentals

KRYS Revenue

Revenue (TTM)

373.2M

Rev. Growth (Yr)

16.65%

Rev. Growth (Qtr)

1.83%

KRYS Earnings

Earnings (TTM)

198.9M

Earnings Growth (Yr)

192%

Earnings Growth (Qtr)

107.04%

KRYS Profitability

EBT Margin

50.10%

Return on Equity

17.48%

Return on Assets

16.04%

Free Cashflow Yield

2.09%

KRYS Investor Care

Shares Dilution (1Y)

0.82%

Diluted EPS (TTM)

6.68

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025333.4M359.2M373.2M0
2024108.5M166.2M241.5M290.5M
202300050.7M
20180000
Get all data in R, Python etc through our Historical Stock Data APIs

About Krystal Biotech Inc

KRYS
Krystal Biotech, Inc., a biotechnology company, develops and commercializes genetic medicines for patients with rare diseases in the United States. It develops beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa; KB105 for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for netherton syndrome; and KB407 for Cystic Fibrosis. The company also develops KB408 for Alpha-1 antitrypsin deficiency; and KB301 for aesthetic skin conditions. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
 CEO
 WEBSITEkrystalbio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES210

Krystal Biotech Inc Frequently Asked Questions

KRYS is the stock ticker symbol of Krystal Biotech Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Krystal Biotech Inc is 7.91 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check KRYS's fair value in chart for subscribers.

The fair value guage provides a quick view whether KRYS is over valued or under valued. Whether Krystal Biotech Inc is cheap or expensive depends on the assumptions which impact Krystal Biotech Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KRYS.

As of Wed Jan 28 2026, KRYS's PE ratio (Price to Earnings) is 39.75 and Price to Sales (PS) ratio is 21.19. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KRYS PE ratio will change depending on the future growth rate expectations of investors.